Bavituximab Withdrawn Phase 1 Trials for Hepatocellular,Carcinoma / Unresectable Hepatocellular Carcinoma / Liver Cancer Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02989870Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma